ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026
Zuclopenthixol
Thioxanthene Derivatives
Sold as CLOPIXOL
GB MHRACA Health Canada
- Drug class
- Thioxanthene Derivatives
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 19
Overview
Zuclopenthixol is an active pharmaceutical ingredient in the Thioxanthene Derivatives group (N05AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | May 15, 2026 |
| CA Canada | Health Canada | 2 | August 15, 2025 |
GBUnited Kingdom· MHRA
17 products
Uses
Not applicable
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PLPI187992738 · revised May 23, 2025
- [2]Health Canada (DPD) · 02230402 · revised August 15, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.